Episcleral implants for topotecan delivery to the posterior segment of the eye

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 4, 2010, Pages 2126-2134

  Carcaboso, Angel M ^a   Chiappetta, Diego A ^a   Opezzo, Javier A W ^a   Höcht, Christian ^a   Fandiñ, Adriana C ^b   Croxatto, J Oscar ^c   Rubio, Modesto C ^a   Sosnik, Alejandro ^a   Abramson, David H ^d   Bramuglia, Guillermo F ^a   Chantada, Guillermo L ^b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

^c Fundacion Oftalmologica Argentina Jorge Malbran   (Argentina)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; TOPOTECAN; ANTINEOPLASTIC AGENT; POLYCAPROLACTONE; POLYESTER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIODEGRADABLE IMPLANT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; EPISCLERAL IMPLANT; EXPERIMENTAL RABBIT; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; SURGICAL TECHNIQUE; VASOCONSTRICTION; ANIMAL; CHOROID; DRUG EFFECT; DRUG IMPLANT; METABOLISM; RABBIT; RETINA; SCLERA; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CHOROID; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; EPINEPHRINE; POLYESTERS; RABBITS; RETINA; SCLERA; TISSUE DISTRIBUTION; TOPOTECAN;

EID: 77951218267     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4050     Document Type: Article

References (45)

1. Cunha-Vaz JG. The blood-retinal barriers system: basic concepts and clinical evaluation. Exp Eye Res. 2004;78:715-721.
2. Wilson TW, Chan HS, Moselhy GM, Heydt DD Jr, Frey CM, Gallie BL. Penetration of chemotherapy into vitreous is increased by cryotherapy and cyclosporine in rabbits. Arch Ophthalmol. 1996; 114:1390-1395.
3. Shields JA, Shields CL, Meadows AT. Chemoreduction in the management of retinoblastoma. Am J Ophthalmol. 2005;140:505-506.
4. Chintagumpala M, Chevez-Barrios P, Paysse EA, Plon SE, Hurwitz R. Retinoblastoma: review of current management. Oncologist. 2007;12:1237-1246.
5. Mendelsohn ME, Abramson DH, Madden T, Tong W, Tran HT, Dunkel IJ. Intraocular concentrations of chemotherapeutic agents after systemic or local administration. Arch Ophthalmol. 1998;116: 1209-1212.
6. Dunkel IJ, Lee TC, Shi W, et al. A phase II trial of carboplatin for intraocular retinoblastoma. Pediatr Blood Cancer. 2007;49:643-648.
7. Abramson DH, Frank CM, Dunkel IJ. A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmology. 1999;106:1947-1950.
8. Chantada GL, Fandino AC, Carcaboso AM, et al. A phase I study of periocular topotecan in children with intraocular retinoblastoma. Invest Ophthalmol Vis Sci. 2009;50:1492-1496.
9. Schmack I, Hubbard GB, Kang SJ, Aaberg TM Jr, Grossniklaus HE. Ischemic necrosis and atrophy of the optic nerve after periocular carboplatin injection for intraocular retinoblastoma. Am J Ophthalmol. 2006;142:310-315.
10. Abramson DH. Periocular chemotherapy for retinoblastoma: success with problems? Arch Ophthalmol. 2005;123:128-129; author reply 129.
11. Frangoul H, Ames MM, Mosher RB, et al. Phase I study of topotecan administered as a 21-day continuous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group. Clin Cancer Res. 1999;5:3956-3962.
12. Chantada GL, Fandino AC, Casak SJ, Mato G, Manzitti J, Schvartzman E. Activity of topotecan in retinoblastoma. Ophthalmic Genet. 2004;25:37-43.
13. Laurie NA, Gray JK, Zhang J, et al. Topotecan combination chemotherapy in two new rodent models of retinoblastoma. Clin Cancer Res. 2005;11:7569-7578.
14. Athale UH, Stewart C, Kuttesch JF, et al. Phase I study of combination topotecan and carboplatin in pediatric solid tumors. J Clin Oncol. 2002;20:88-95.
15. Hughes PM, Olejnik O, Chang-Lin JE, Wilson CG. Topical and systemic drug delivery to the posterior segments. Adv Drug Deliv Rev. 2005;57:2010-2032.
16. Carcaboso AM, Bramuglia GF, Chantada GL, et al. Topotecan vitreous levels after periocular or intravenous delivery in rabbits: an alternative for retinoblastoma chemotherapy. Invest Ophthalmol Vis Sci. 2007;48:3761-3767.
17. Houghton PJ, Cheshire PJ, Myers L, Stewart CF, Synold TW, Houghton JA. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol. 1992;31:229-239.
18. Gaudana R, Jwala J, Boddu SH, Mitra AK. Recent perspectives in ocular drug delivery. Pharm Res. 2009;26:1197-1216.
19. Burke TG, Bom D. Camptothecin design and delivery approaches for elevating anti-topoisomerase I activities in vivo. Ann N Y Acad Sci. 2000;922:36-45.
20. Carcaboso AM, Chiappetta DA, Hocht C, et al. In vitro/in vivo characterization of melt-molded gabapentin-loaded poly(epsiloncaprolactone) implants for sustained release in animal studies. Eur J Pharm Biopharm. 2008;70:666-673.
21. Rittenhouse KD, Pollack GM. Microdialysis and drug delivery to the eye. Adv Drug Deliv Rev. 2000;45:229-241.
22. de Lange EC, de Boer AG, Breimer DD. Methodological issues in microdialysis sampling for pharmacokinetic studies. Adv Drug Deliv Rev. 2000;45:125-148.
23. Nitschke R, Parkhurst J, Sullivan J, Harris MB, Bernstein M, Pratt C. Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol. 1998;20:315-318.
24. Leger F, Loos WJ, Bugat R, et al. Mechanism-based models for topotecan-induced neutropenia. Clin Pharmacol Ther. 2004;76: 567-578.
25. Sasaki H, Nagano T, Sakanaka K, et al. One-side-coated insert as a unique ophthalmic drug delivery system. J Control Release. 2003; 92:241-247.
26. Wang G, Tucker IG, Roberts MS, Hirst LW. In vitro and in vivo evaluation in rabbits of a controlled release 5-fluorouracil subconjunctival implant based on poly(D,L-lactide-co-glycolide). Pharm Res. 1996;13:1059-1064.
27. Pontes de Carvalho RA, Krausse ML, Murphree AL, Schmitt EE, Campochiaro PA, Maumenee IH. Delivery from episcleral exoplants. Invest Ophthalmol Vis Sci. 2006;47:4532-4539.
28. Tsui JY, Dalgard C, Van Quill KR, et al. Subconjunctival topotecan in fibrin sealant in the treatment of transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci. 2008;49:490-496.
29. Sun H, Mei L, Song C, Cui X, Wang P. The in vivo degradation, absorption and excretion of PCL-based implant. Biomaterials. 2006;27:1735-1740.
30. Santana VM, Furman WL, Billups CA, et al. Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J Clin Oncol. 2005;23:4039-4047.
31. Shenderova A, Burke TG, Schwendeman SP. The acidic microclimate in poly(lactide-co-glycolide) microspheres stabilizes camptothecins. Pharm Res. 1999;16:241-248.
32. Rodriguez-Galindo C, Wilson MW, Chantada G, et al. Retinoblastoma: one world, one vision. Pediatrics. 2008;122:e763-770.
33. Miller DJ, Li SK, Tuitupou AL, et al. Passive and oxymetazolineenhanced delivery with a lens device: pharmacokinetics and efficacy studies with rabbits. J Ocul Pharmacol Ther. 2008;24:385-391.
34. Abramson DH, Frank CM, Chantada GL, et al. Intraocular carboplatin concentrations following intravenous administration for human intraocular retinoblastoma. Ophthalmic Genet. 1999;20:31-36.
35. Nork TM, Kim CB, Shanmuganayagam D, Van Lysel MS, Ver Hoeve JN, Folts JD. Measurement of regional choroidal blood flow in rabbits and monkeys using fluorescent microspheres. Arch Ophthalmol. 2006;124:860-868.
36. Davis FA. The anatomy and histology of the eye and orbit of the rabbit. Trans Am Ophthalmol Soc. 1929;27:400 402-441.
37. Boubriak OA, Urban JP, Akhtar S, Meek KM, Bron AJ. The effect of hydration and matrix composition on solute diffusion in rabbit sclera. Exp Eye Res. 2000;71:503-514.
38. Olsen TW, Edelhauser HF, Lim JI, Geroski DH. Human scleral permeability: effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest Ophthalmol Vis Sci. 1995;36:1893-1903.
39. Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci. 1998;87:1479-1488.
40. Ahmed I, Gokhale RD, Shah MV, Patton TF. Physicochemical determinants of drug diffusion across the conjunctiva, sclera, and cornea. J Pharm Sci. 1987;76:583-586.
41. Cruysberg LP, Franklin AJ, Sanders J, et al. Effective transscleral delivery of two retinal anti-angiogenic molecules: carboxyamidotriazole (CAI) and 2-methoxyestradiol (2ME2). Retina. 2005;25: 1022-1031.
42. Okabe K, Kimura H, Okabe J, et al. Effect of benzalkonium chloride on transscleral drug delivery. Invest Ophthalmol Vis Sci. 2005;46:703-708.
43. Cheruvu NP, Kompella UB. Bovine and porcine transscleral solute transport: influence of lipophilicity and the choroid-Bruch's layer. Invest Ophthalmol Vis Sci. 2006;47:4513-4522.
44. Zhang T, Xiang CD, Gale D, Carreiro S, Wu EY, Zhang EY. Drug transporter and cytochrome P450 mRNA expression in human ocular barriers: implications for ocular drug disposition. Drug Metab Dispos. 2008;36:1300-1307.
45. Chen C, Mireles RJ, Campbell SD, et al. Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005;33:537-546.